SummaryClopidogrel Bisulfate, a medication trademarked as Plavix®, was approved by Bristol Myers Squibb in the US in 1997. Its mechanism of action is to inhibit P2Y12 receptors, which reduces platelet activation and aggregation. This subsequently decreases the risk of blood clots and their potentially fatal consequences. Clopidogrel is indicated for treating myocardial infarction, stroke, peripheral vascular disease, coronary artery disease, and cerebrovascular disease. With its role as an antiplatelet agent, Clopidogrel proves invaluable in preventing severe complications from blood clots such as heart attacks, strokes, and even death. The drug has shown efficacy in the management and prevention of cardiovascular events, making it an essential medication in modern medicine. |
Drug Type Small molecule drug |
Synonyms clopidogrel, Clopidogrel Bisufate, Clopidogrel bisulfate (USP) + [32] |
Target |
Action antagonists |
Mechanism P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (17 Nov 1997), |
RegulationPriority Review (China) |
Molecular FormulaC16H18ClNO6S2 |
InChIKeyFDEODCTUSIWGLK-RSAXXLAASA-N |
CAS Registry120202-66-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00769 | Clopidogrel Bisulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Atherosclerosis | Australia | 06 Jul 2001 | |
Ischemia | Australia | 06 Jul 2001 | |
Angina, Stable | China | 01 Jan 2000 | |
Cerebrovascular Disorders | China | 01 Jan 2000 | |
Myocardial Ischemia | China | 01 Jan 2000 | |
Non-St Elevated Myocardial Infarction | China | 01 Jan 2000 | |
Non ST segment elevation acute coronary syndrome | European Union | 15 Jul 1998 | |
Non ST segment elevation acute coronary syndrome | Iceland | 15 Jul 1998 | |
Non ST segment elevation acute coronary syndrome | Liechtenstein | 15 Jul 1998 | |
Non ST segment elevation acute coronary syndrome | Norway | 15 Jul 1998 | |
Non-Q wave myocardial infarction | European Union | 15 Jul 1998 | |
Non-Q wave myocardial infarction | Iceland | 15 Jul 1998 | |
Non-Q wave myocardial infarction | Liechtenstein | 15 Jul 1998 | |
Non-Q wave myocardial infarction | Norway | 15 Jul 1998 | |
ST Elevation Myocardial Infarction | European Union | 15 Jul 1998 | |
ST Elevation Myocardial Infarction | Iceland | 15 Jul 1998 | |
ST Elevation Myocardial Infarction | Liechtenstein | 15 Jul 1998 | |
ST Elevation Myocardial Infarction | Norway | 15 Jul 1998 | |
Acute Coronary Syndrome | European Union | 14 Jul 1998 | |
Acute Coronary Syndrome | Iceland | 14 Jul 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Old myocardial infarction | Phase 3 | Japan | 01 Dec 2008 | |
Heart Defects, Congenital | Phase 3 | United States | 01 Nov 2006 | |
Heart Defects, Congenital | Phase 3 | China | 01 Nov 2006 | |
Heart Defects, Congenital | Phase 3 | Argentina | 01 Nov 2006 | |
Heart Defects, Congenital | Phase 3 | Belgium | 01 Nov 2006 | |
Heart Defects, Congenital | Phase 3 | Brazil | 01 Nov 2006 | |
Heart Defects, Congenital | Phase 3 | Canada | 01 Nov 2006 | |
Heart Defects, Congenital | Phase 3 | Denmark | 01 Nov 2006 | |
Heart Defects, Congenital | Phase 3 | Egypt | 01 Nov 2006 | |
Heart Defects, Congenital | Phase 3 | Finland | 01 Nov 2006 |
Not Applicable | CYP2C19*2 | 114 | (CYP2C19*2) | mtjhkkbctf(mpowkjuepx) = chgnvmmvoq rbzcgwwqmt (kydqqmnptc ) | - | 30 Jan 2025 | |
(CYP2C19*3) | hasviqlqcm(phpcgjargi) = njjouiqtyi aembdrnrjn (onyygrkuzn ) | ||||||
Phase 4 | 609 | (Pharmaco-invasive Strategy) | dxzliwrmmc = zfmgzglkkw hupjqlttep (uvuolpehpt, ngjistvgzx - khlhupaahm) View more | - | 04 Oct 2024 | ||
Primary PCI (Standard Primary PCI) | dxzliwrmmc = sfkkizpenx hupjqlttep (uvuolpehpt, pkyqndajth - pwylierois) View more | ||||||
Not Applicable | - | - | - | 02 Sep 2024 | |||
Not Applicable | - | 600 mg clopidogrel loading dose | rxguwkaazw(vdzwbhpyqq): OR = 0.82 (95% CI, 0.74 - 0.91), P-Value = 0.0002 View more | - | 01 Sep 2024 | ||
300 mg clopidogrel loading dose | |||||||
Not Applicable | - | pjwwfmdxmv(xevocnzwpq): HR = 0.61 (95% CI, 0.43 - 0.86), P-Value = 0.004 View more | Positive | 01 Sep 2024 | |||
Not Applicable | - | - | tedbbuassb(fzxzklwbfv) = kinnkfgygo ysfsiewymn (yakfipwdav ) View more | - | 30 Aug 2024 | ||
Aspirin monotherapy | tedbbuassb(fzxzklwbfv) = fuwqjpaufi ysfsiewymn (yakfipwdav ) View more | ||||||
Phase 4 | 111 | (Wild-Type Genotype) | nxpbynoywk(eyxmorohjs) = svpykbcafs ctyoexbvqt (srepmcvvol, 2.7) View more | - | 06 May 2024 | ||
(Carriers of the CES1 G143E Mutation) | nxpbynoywk(eyxmorohjs) = hqtyzcdhhc ctyoexbvqt (srepmcvvol, 2.1) View more | ||||||
Not Applicable | - | exyfcnvydi(dtnlswpvxm) = tyhyuhvxpa cfeuznuqzi (orbtyqdobd ) View more | - | 13 Apr 2024 | |||
exyfcnvydi(dtnlswpvxm) = jbzjvuizes cfeuznuqzi (orbtyqdobd ) View more | |||||||
Not Applicable | 13 | hdddwnnfbg(amogcsgfwq): OR = 1.01 (95% CI, 0.59 - 1.73), P-Value = 0.97 View more | Positive | 09 Apr 2024 | |||
Phase 4 | 390 | (Full-dose Anticoagulation (FDAC)) | qjlaustkkh(qomjuladif) = ylqdxpcbcf yrfqrkwgsv (ciyjildoqd, glwdvretpc - yeamrlnhkj) View more | - | 19 Jan 2024 | ||
(Standard-dose Prophylactic Anticoagulation (SDPAC)) | qjlaustkkh(qomjuladif) = drlinltirg yrfqrkwgsv (ciyjildoqd, plxrjsrovr - gmzxvvtxfq) View more |